Solvd Health received FDA approval to use its AvertD pharmacogenomic test for opioid use disorder with blood samples, expanding beyond cheek swabs. The test analyzes 15 genetic variants linked to susceptibility to OUD risk and was previously approved for use with cheek swab collection in late 2023. The company said blood-based collection may make clinical integration easier for health systems working within existing workflows. Solvd also faced earlier scrutiny after critics argued the evidence base did not support its clinical utility, leading to calls for FDA reconsideration following a reported lack of efficacy standards. In this update, FDA approval repositions AvertD as a more deployable genetic risk tool for OUD evaluation, though the earlier controversy points to the importance of ongoing performance evidence in real-world settings.